I just posted the following in the comments section of that article (assuming it doesn't get censored out):
Well, I must say this is definitely from a "Fool's" perspective, and not just Motley Fool. When comparing Lovaza and its coming generics to Vascepa, especially if the ANCHOR usage is approved, why would anyone not choose Vascepa? That would be like buying a brand-new, high-performance luxury car and then filling it with the cheapest gas you can find. When it comes to ones personal health, you would think someone would take the best medicine they can for their ailment (in this case, very high triglycerides and with ANCHOR approval high triglycerides).
yes, they'll keep trying to manipulate until AMRN shows obvious script growth traction. At that point, big investors will move in and drive up the pps and the morons will move somewhere else, but until then we will get manipulated. It's easy to do while uncertainty lingers.